Class / Patent application number | Description | Number of patent applications / Date published |
514024000 | S-glycoside | 81 |
20080312164 | ISOTHIOCYANATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME - The present invention provides glucosinolate and isothiocyante compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents. | 12-18-2008 |
20090176717 | GALACTOSIDES AND THIODIGALACTOSIDES AS INHIBITORS OF PA-IL LECTIN FROM PSEUDOMONAS - Compositions and methods are provided related to | 07-09-2009 |
20090186834 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS - Various azetidinone, pyrrolidine, imidazolidine, and oxazolidine derivatives are described, as are pharmaceutical compositions containing these compounds and methods of treatment of diseases using these compounds. Other embodiments are also described. | 07-23-2009 |
20090247477 | Methods of suppressing uv light-induced skin carcinogenesis - Administration of the isothiocyanate protects against UV light-induced skin carcinogenesis. In particular, topical application or dietary administration of isothiocyanate sulforaphane after exposure to UV radiation provides effective protection against skin tumor formation. Sulforaphane analogs and glucosinolates also can be employed. Lotions useful for suppressing UV light-induced skin carcinogenesis also are provided. | 10-01-2009 |
20090275524 | NOVEL HYPOCHOLESTEROLEMIC COMPOUNDS - The present invention relates to novel hypocholesterolemic compounds of formula (I) useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels as well as to pharmaceutical compositions comprising said compounds alone or in combination with other active agents | 11-05-2009 |
20090305999 | UTILIZATION OF HYPERTENSION/HYPERCARDIA-PREVENTING EFFECT OF D-ALLOSE - The object is to provide a novel application of D-allose (e.g., use for prevention of hypertension or hypercardia). Thus, disclosed is a composition for preventing the increase in blood pressure which comprises D-allose as an active ingredient; or a composition containing D-allose and/or a derivative thereof, preferably in an amount of 0.1 to 50% by weight. Preferably, the composition is in a form selected from the group consisting of a food additive, a food material, a beverage/food, a health beverage/food, a pharmaceutical and a feeding stuff which can be used for the prevention and treatment of a cardiovascular system disorder (e.g., hypertension, hypercardia). The increase in blood pressure may be caused by salt-sensitive hypertension. Also disclosed is use of D-allose for preventing the increase in blood pressure (excluding medical practices). | 12-10-2009 |
20090306000 | TANAPROGET DERIVATIVES, METABOLITES, AND USES THEREOF - A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided. | 12-10-2009 |
20090318370 | NOVEL GLYCOCONJUGATED CHLORIN DERIVATIVES AND METHOD OF PRODUCING THE SAME - Disclosed is a novel glycoconjugated chlorin derivative which is useful as a substance for photodynamic therapy, is stable, and can act a photosensitizer having high phototoxicity even when used in a small quantity. Also disclosed is a method of producing the derivative. Specifically disclosed are a S-glycosylated chlorin derivative represented by the following general formula (1) and a metal complex thereof. In the general formula (1), X | 12-24-2009 |
20090318371 | TOPICAL ANTIACNE PREPARATIONS CONTAINING RETINOID (TAZAROTENE OR ADAPALENE), ANTIBIOTIC (CLINDAMYCIN PHOSPHATE) AND/OR KERATOLYTIC (MICROSPONGED BENZOYL PEROXIDE) - The present invention relates to a topical preparation for treating acne in the form of a gel and cream comprising Retinoid (Tazarotene or Adapalene) Antibiotic (Clindamycin Phosphate) and/or Keratolytic (Benzoyl Peroxide in microsponges) as active ingredients and a carrier formulated with all or some of the following components: Polyoxyl 35 castor oil Propylene glycol Glycerine, Carbomer, Triethanolamine, EDTA, Emulsifying nonionic wax (Polawax) Ethanol Antioxidants and Preservatives. The present invention advantages regarding state of the art compositions are based on the fact that the present antiacne composition contains a Retinoid, and Antibiotic and/or a Keratolytic agent which allow the control of every kind of acne from mild to vulgar offering less adverse effects. | 12-24-2009 |
20100120703 | COMPOSITIONS AND METHODS FOR TREATING CANCER - Pharmaceutical compositions comprising sinigrin and a pharmaceutically acceptable carrier and use thereof for treating liver cancer. A method for treatment of liver cancer in a subject comprising administering to the subject in need thereof and suffering from cancer, a pharmaceutically effective amount of sinigrin, is also provided. | 05-13-2010 |
20100173855 | Dermatological Formulations - Aqueous preparations of substantially equimolor amounts of a zinc salt and clindamycin phosphate form a polymer useful in the topical treatment of acne and rosacea, with very low systemic levels of clindamycin. | 07-08-2010 |
20100184711 | Alpha-GLYCOSYL THIOLS AND alpha-S-LINKED GLYCOLIPIDS - The present invention relates to stereoselective methods for the preparation of α-glycosyl thiols and α-S-linked glycosylceramides. | 07-22-2010 |
20100190728 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents - Disclosed are analgesic-related compositions and methods of using the compositions for modulation of analgesic receptor activity. The compositions and methods are useful for reducing pain, as well as for therapeutic intervention of addictions or other diseases or disorders amenable to treatment or prophylaxis by modulation of analgesic receptor signaling. | 07-29-2010 |
20100204162 | SUBSTRATE REDUCTION THERAPY - The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype. | 08-12-2010 |
20100210570 | LINCOMYCIN DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT - An objective of the present invention is to provide compounds of formula (1) or their pharmacologically acceptable salts or solvates wherein A represents aryl; R | 08-19-2010 |
20100210571 | TOPICAL FORMULATIONS FOR TREATMENT OF SKIN DISORDERS - Topical compositions and methods of using same for treating skin disorders or conditions comprising a storage-stable mixture of a benzoyl peroxide dispersion, clindamycin or pharmaceutically acceptable salts or esters thereof, and a pharmaceutically acceptable carrier. | 08-19-2010 |
20110021447 | ACNE TREATMENT COMPOSITION AND METHODS FOR USING - An acne treatment composition is provided according to the present invention. The acne treatment composition includes an effective amount of an anti-acne component to provide anti-acne properties to skin tissue, an effective amount of a skin bounding polymer component to provide sustained release of the anti-acne component over a prolonged period of time after application of the acne treatment composition to skin tissue, and water. A method of using an acne treatment composition is provided. | 01-27-2011 |
20110053870 | USE OF ISOTHIOCYANATE DERIVATIVES AS ANTI-MYELOMA AGENTS - The invention concerns the use of glucomoringin and of its des-thio-glucoside having the following formulae (I, II): for the preparation of a medicament for the treatment of myeloma. | 03-03-2011 |
20110053871 | METHODS OF REGULATING ACTIN CYTOSKELETAL REARRANGEMENT AND INTERCELLULAR GAP FORMATION - Methods are described for preventing or reducing cytoskeletal rearrangement and intercellular gap formation by contacting cells with an aminoalkyl glucosaminide phosphate. In particular, the disclosed methods can be used to prevent or reduce actin cytoskeletal rearrangement and/or intracellular gap formation related to ischemic or ischemia-reperfusion events and to prevent or alleviate diseases or conditions related to increased actin cytoskeletal rearrangement. | 03-03-2011 |
20110098238 | ELUCIDATING LIGAND-BINDING INFORMATION BASED ON PROTEIN TEMPLATES - A method, computer-readable medium, and system for identifying compounds from chemical libraries that can be used for the therapeutic treatment of a disease or used as lead compounds in a drug development program. In particular, information from homologous proteins is used to predict, for a target protein, molecular functions that can be used to screen libraries of compounds for individual compounds that are predicted to have high binding affinities for the target protein. | 04-28-2011 |
20110124586 | EXTERNAL PREPARATION FOR SKIN, AND WRINKLE-REPAIRING AGENT - Provided are an external preparation for skin and a wrinkle-reducing agent exhibiting an excellent effect of reducing wrinkles that develop particularly in an exposed site along with aging, and having high safety. The external preparation for skin and the wrinkle-reducing agent each contain an alkyl thioglycoside represented by the general formula (1): G-SR | 05-26-2011 |
20110195919 | COMBINATION THERAPY FOR ACNE VULGARIS COMPRISING ADMINISTRATION OF ADAPALENE 0.3% GEL AND CLINDAMYCIN/BENZOYL PEROXIDE GEL - A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®. | 08-11-2011 |
20110218159 | METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 - Methods of improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as compounds and pharmaceutical compositions useful therein. | 09-08-2011 |
20110251141 | COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS - A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection. | 10-13-2011 |
20110306566 | TOPICAL SKIN TREATMENT KITS - This invention relates to benzoyl peroxide products for skin treatment, and more particularly to a kit containing a benzoyl peroxide product and a topical moisturizing product. In one embodiment the kit contains BenzaClin® brand clindamycin-benzoyl peroxide gel and Viscontour® brand hyaluronic acid serum. | 12-15-2011 |
20120094942 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Also provided are methods directed to the modulation of circulating concentrations of one or more of GLP-1 (total), GLP-1 (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon. | 04-19-2012 |
20120108527 | POLYMERIC TOPICAL COMPOSITIONS - The present invention relates to topical antibacterial compositions. The compositions comprise an antibacterial agent such as mupirocin, water, a polymer and a volatile solvent present in an amount of less than about 40%. The invention also relates to methods of treatment by administering the compositions to a patient in need thereof, and to the use of such compositions in the treatment of bacterial conditions. | 05-03-2012 |
20120129794 | APPARATI, METHODS, AND COMPOSITIONS FOR UNIVERSAL MICROBIAL DIAGNOSIS, DETECTION, QUANTIFICATION, AND SPECIMEN-TARGETED THERAPY - Microbial ecology of a specimen is evaluated using an approach (Level I) that utilizes nucleic acid amplification with specific gene primers that will identify panels of microorganisms and antibiotic-resistance factors generating a diagnostic report (optionally with quantification of each microorganism or antibiotic-resistance factor) and an approach (Level II) that utilizes universal or semi-universal primers to amplify conserved genes at a general or specific taxonomic level that are tagged specimen specifically using a genetic or chemical marker that is specific to the specimen from which it was derived, then sequencing the amplified products with highly-parallel, high-throughput technology to provide comprehensive sequences of the microbial population in the specimen followed by analysis of this sequence information and specific targeted information from Level I and/or Level II to generate a comprehensive analysis, interpretation, and/or diagnostic report. | 05-24-2012 |
20120165277 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS - Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, where in the galectin is preferably a galectin-3. The novel compounds are defined by the general formula: | 06-28-2012 |
20120172320 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 - Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture. | 07-05-2012 |
20120202756 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS - The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side-effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics. | 08-09-2012 |
20120245107 | METHODS OF REDUCING THE PROLIFERATION AND VIABLILITY OF MICROBIAL AGENTS - The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents. | 09-27-2012 |
20120258922 | SYNERGISTIC INHIBITION OF LOW-DENSITY LIPOPROTEIN OXIDATION - The invention provides use of a composition comprising a plant, plant parts, and extracts thereof having high levels of glucoraphanin and/or sulforaphane and tocopherols. Also provided are glucoraphanin and/or sulforaphane, in combination with tocopherols, where the overall composition synergistically inhibits oxidation of low-density lipoproteins. Methods of producing a food from such a plant are also provided. | 10-11-2012 |
20120277171 | Warmi.RTM., natural alternative for the treatment of menopause - Warmi®, composed of glucosinolates, β-sitosterol and citrus flavonoids (hesperidin), is as effective as HRT in reducing menopausal symptoms, Warmi® promotes a healthy cardiovascular system, supports hormonal balance and emotional well-being, improving the quality of life of women during perimenopause and menopause. All of these and the lack of side effects make Warmi® an ideal natural alternative to conventional HRT. | 11-01-2012 |
20130045932 | RETINOID TOPICAL COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS - A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition. | 02-21-2013 |
20130053332 | USE - The present invention relates to a composition comprising a high glucosinolate Cruciferous vegetable (such as a high glucosinolate broccoli) having a high level of glucosinolate and/or at least one derivative thereof for use in the treatment or prevention of a cardiovascular disease or for use in promoting heart and/or cardiovascular health. | 02-28-2013 |
20130053333 | Aminoquinoline Derivatives - This invention relates to novel aminoquinoline derivatives of Formula (I) or Ia, or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an aminoquinoline derivative, such as a derivative of primaquine. | 02-28-2013 |
20130102548 | PHARMACEUTICAL DELIVERY SYSTEM - A pharmaceutical formulation to treat vaginal conditions in a human patient comprises:
| 04-25-2013 |
20130116203 | ISOTHIOCYNATES AND GLUCOSINOLATE COMPOUNDS AND ANTI-TUMOR COMPOSITIONS CONTAINING SAME - The present invention provides glucosinolate and isothiocyanate compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents. | 05-09-2013 |
20130123203 | METHODS AND COMPOSITIONS FOR TREATMENT OF AUTISM - Disclosed herein are methods and compositions for treating autism. Disclosed herein are methods and compositions for treating an autism spectrum disorder. | 05-16-2013 |
20130143827 | TANAPROGET DERIVATIVES, METABOLITES, AND USES THEREOF - A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided. | 06-06-2013 |
20130157965 | Prevention and Treatment of Oxidative Stress Disorders by Glutathione and Phase II Detoxification Enzymes - The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders. | 06-20-2013 |
20130165395 | METHODS OF TREATING DIABETES - Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders. | 06-27-2013 |
20130172279 | COMPOSITION FOR TOPICAL TREATMENT OF MIXED VAGINAL INFECTIONS - A pharmaceutical composition comprises (a) an antibacterial agent in an antibacterially effective amount, illustratively comprising clindamycin or a pharmaceutically acceptable salt or ester thereof; and (b) an antifungal agent in an antifungally effective amount, illustratively comprising butoconazole or a pharmaceutically acceptable salt or ester thereof. The composition is adapted for application in a unit dose amount to a vulvovaginal surface and has at least one nonlipoidal internal phase and at least one lipoidal external phase that is bioadhesive to the vulvovaginal surface. The composition is useful for administration to a vulvovaginal surface to treat a mixed bacterial vaginosis and vulvovaginal candidiasis infection. | 07-04-2013 |
20130225514 | C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF - The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R | 08-29-2013 |
20130231296 | NEW DRUG COMBINATIONS FOR THE TREATMENT OF MALARIA - The present invention relates to pharmaceutical preparations/compositions comprising 3-N-formyl hydroxy amino propyl phosphonic acid derivatives or 3-N-acetyl hydroxy amino propyl phosphonic acid derivatives as active ingredients in combination with Piperaquine. | 09-05-2013 |
20130288988 | Diagnostic Methods and Markers for Bacterial Vaginosis - A method of diagnosing bacterial vaginosis in a woman, which involves determining an amount of each of more than one BV-associated bacterium in a vaginal sample obtained from the female and assessing a BV status of the female based on the amount of each of the more than one BV-associated bacterium in the sample. | 10-31-2013 |
20130338088 | SELF SOLIDIFYING BIOERODIBLE BARRIER IMPLANT - Provided are bioerodible compositions that can be implanted into cavities or mammalian tissue as a liquid or semi-liquid and which solidify upon exposure of the body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens. | 12-19-2013 |
20140018308 | METHODS OF LOWERING BLOOD PRESSURE - Methods of improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as compounds and pharmaceutical compositions useful therein. | 01-16-2014 |
20140018309 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 01-16-2014 |
20140031302 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES - The present invention includes novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and their syntheses. The present invention also provides a pharmaceutical composition comprising the present compound and the use of the compound as inhibitors of kinases and of the enzyme family known as heat shock protein 90 (HSP90). | 01-30-2014 |
20140051649 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 02-20-2014 |
20140057859 | Hyaluronate Compositions - The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same. | 02-27-2014 |
20140080769 | SUBSTRATE REDUCTION THERAPY - The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype. | 03-20-2014 |
20140088028 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds of formula (I) with substituents as specified in Claim | 03-27-2014 |
20140135277 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE - Sulfanyl-tetrahydropyran-based compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment of diseases and disorders such as diabetes and obesity are disclosed. | 05-15-2014 |
20140148398 | METHODS OF TREATING GIARDIASIS - Compounds useful for the treatment of giardiasis are described. | 05-29-2014 |
20140187503 | DIAGNOSTIC METHOD - It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis. | 07-03-2014 |
20140200189 | ARTONI I TO TREAT RESISTANT INFECTIOUS STAPHYLOCOCCUS AUREUS - Artonin I is reported to treat multi-drug resistant | 07-17-2014 |
20140200190 | NOVEL GALACTOSIDE INHIBITORS OF GALECTINS - Compounds having an effect as i.a. galectin inhibitors, to the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal, wherein the galectin is preferably a galectin-3. The novel compounds are defined by the general formula: | 07-17-2014 |
20140235560 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 08-21-2014 |
20140256658 | Antibiotic Conjugates - The present invention describes antibiotic conjugates. These single drug entities are formed connecting one antibiotic with another antibiotic. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. | 09-11-2014 |
20140303100 | COMPOSITIONS FOR DENTAL CARE - This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis. | 10-09-2014 |
20140303101 | COMPOSITIONS FOR DENTAL CARE - This invention pertains to dental care compositions with antimicrobial benefits. In particular, the invention provides for compositions of oral tissue-adherent salts that release biocidal ions on a controlled release basis and thereby provide and maintain an essentially uniform concentration of biocidal ions above the MBC or MIC of the target bacteria at the site of application in the mouth for an extended period of time. The compositions are useful for treating or preventing oral diseases resulting from bacteria, fungal or yeast infections, such as caries, gingivitis, periodontal disease and candidiasis. | 10-09-2014 |
20140309178 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 - Inhibitors of sodium glucose cotransporter 1 (SGLT1), compositions comprising them, and methods of their use to treat diseases and disorders such as diabetes are disclosed. Particular compounds are of the formula: | 10-16-2014 |
20140371163 | COMBINATION THERAPY FOR ACNE VULGARIS COMPRISING ADMINISTRATION OF ADAPALENE 0.3% GEL AND CLINDAMYCIN/BENZOYL PEROXIDE GEL - A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®. | 12-18-2014 |
20150011486 | GLYCOSYLATED ANTITUMOR ETHER LIPIDS AS NOVEL CANCER STEM CELL CYTOTOXIC AGENTS - Glycosylated antitumor ether lipids (GAELs) are effective cytotoxic agents against cancer stem cells. Furthermore, combining GAELs which kill cells by a caspase-independent pathway with agents that kill cells by apoptosis will lead to elimination of the differentiated tumor cells and the undifferentiated cancer stem cells leading to an elimination of the tumor and preventing recurrence. | 01-08-2015 |
20150018290 | INDUCERS OF HEMATOPOIESIS AND FETAL GLOBIN PRODUCTION FOR TREATMENT OF CYTOPENIAS AND HEMOGLOBIN DISORDERS - The present invention generally relates to compositions containing chemical compounds and compositions and pharmaceutical formulations of the compounds which increase the expression of total hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other blood cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia, and other blood cell deficiencies and blood disorders. The invention also relates to methods for administering these compositions to subjects and for use as medical aids for the treatment and prevention of blood and other disorders. | 01-15-2015 |
20150080324 | Aryl Derivatives And Uses Thereof - The present invention relates to antimalarial compounds and their use against protozoa of the genus | 03-19-2015 |
20150111840 | COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2 - Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture. | 04-23-2015 |
20150322105 | RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF - The present invention provides novel ruthenium compounds of Formula (I): | 11-12-2015 |
20150366884 | COMPOSITIONS AND METHODS FOR CANCER THERAPY - The invention provides compositions and methods to treat cancer with an agent that selectively promotes cancer cell death relative to non-malignant cells by mechanisms that include increased oxidative stress (“a therapeutic agent”) or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier. | 12-24-2015 |
20150374680 | POCHOXIME CONJUGATES USEFUL FOR THE TREATMENT OF HSP90 RELATED PATHOLOGIES - The present invention includes novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and their syntheses. The present invention also provides a pharamceutical composition comprising the present compound and the use of the compound as inhibitors of kinases and of the enzyme family known as heat shock protein 90 (HSP90). | 12-31-2015 |
20160022718 | METHODS OF LOWERING BLOOD PRESSURE - Methods of improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as compounds and pharmaceutical compositions useful therein. | 01-28-2016 |
20160022722 | METHODS AND MATERIALS FOR REDUCING THE RISK OF INFECTIONS - This document relates to methods and materials for reducing the risk of infection after a shoulder surgery or medical procedure. For example, this document relates to methods and materials for using a topical composition containing clindamycin or erythromycin to reduce the risk of or to prevent infection associated with shoulder surgeries or medical procedures. | 01-28-2016 |
20160038485 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS - Disclosed herein are novel compounds, their use in the treatment and prevention of joint and/or cartilage inflammation that provide an alternative to the NSAIDS and selective COX-2 inhibitors by activating endogenous detoxifying cellular defense mechanisms that act to neutralize toxic cellular intermediate. These compounds are PPAR-alpha agonists and/or phase 2 gene activators. | 02-11-2016 |
20160096858 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 04-07-2016 |
20160106773 | TREATMENT FOR DISEASES RELYING ON DISCOVERY THAT THIOREDOXIN MEDIATES NITRIC OXIDE RELEASE IN CELLS - Patients having a disease associated with high level of thioredoxin system activity or a requirement for nitric oxide, e.g. large cell lymphoma or restenosis, are treated with a thioredoxin reductase inhibitor, e.g. auranofin or arsenic trioxide, and a nitric oxide donating compound, e.g. isosorbide mononitrite or isosorbide dinitrite or nitroglycerin or S-nittrosothiol. Patients having a disease associated with nitric oxide synthase overexpression or increased activity, e.g. Parkinson's disease or septic shock or pancreatic cancer, are treated with Trx/Trx reductase upregulator, e.g. aptamer that binds to thioredoxin reductase inhibitor, and agent causing depletion of nitric oxide (or adduct thereof), e.g. L-NMMA or L-NAME or minocycline or ascorbate or N-acetylcysteine. | 04-21-2016 |
20160143876 | MAINTENANCE THERAPY REGIME/REGIMEN FOR THE TREATMENT OF ACNE - A maintenance therapy regimen is described for the treatment of acne related diseases. The novel therapy regimen follows a course of oral antibiotic therapy with a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide. | 05-26-2016 |
20160145284 | LIPID-BASED PLATINUM COMPOUNDS AND NANOPARTICLES - The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum based compounds, nanoparticles and compositions comprising said platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by employing aforesaid carbene compounds, platinum based compounds, nanoparticles and compositions thereof. | 05-26-2016 |
20160158261 | Antibiotic Kit and Composition and Uses Thereof - The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. | 06-09-2016 |